GERD

Implantica's RefluxStop™ health economic research, showing superior cost-effectiveness, has received top-recognition at ISPOR, the world's leading European Health-Economics Conference

Retrieved on: 
Giovedì, Novembre 16, 2023
International Society, Research, Pharmacoeconomics, GERD, Patient, CET, University of York, HTA, Certification, Abstract, ISPOR, Systematic review, Health technology assessment, Medical device, Payment

The in-depth and comprehensive health economic analyses in Sweden and Switzerland including four successful abstracts demonstrates that RefluxStop™ is more cost-effective against existing treatment options.

Key Points: 
  • The in-depth and comprehensive health economic analyses in Sweden and Switzerland including four successful abstracts demonstrates that RefluxStop™ is more cost-effective against existing treatment options.
  • The Quality-of-Life analysis of GERD patients clearly showed that surgical management of GERD leads to a better Quality-of-Life than disease management through medication.
  • ISPOR is globally recognized as the leading scientific and educational organization for health economics and outcomes research (HEOR) and its use in the healthcare decision-making process.
  • To present such impactful economic data and be selected in the "Top 5% poster category" at ISPOR is a true honor for Implantica.

Implantica's RefluxStop™ makes an impact at the leading Annual European Foregut Society Meeting

Retrieved on: 
Mercoledì, Novembre 15, 2023
Associate, EFS, GERD, Surgeon, Teaching hospital, Patient, CET, ARB, Scientific programming language, Humble, Texas, GI, Certification, Congress, Quality of life, Deutsche Medizinische Wochenschrift, Health

), a medtech company at the forefront of bringing advanced technology into the body, announces participation in the 3rd Annual EFS (European Foregut Society) Congress in Milan, Italy in early November.

Key Points: 
  • ), a medtech company at the forefront of bringing advanced technology into the body, announces participation in the 3rd Annual EFS (European Foregut Society) Congress in Milan, Italy in early November.
  • The Scientific Program at EFS included the symposium, 'Reconstruction of the Anti-Reflux Barrier (ARB) with RefluxStop™- an innovative approach.'
  • This well-attended event, filled with lively conversation, offered an opportunity to learn directly from experts with real-world experience performing the RefluxStop™ procedure.
  • Dr. Forsell goes on to say, "The 3rd Annual EFS Meeting gave Implantica the opportunity to spotlight RefluxStop™ and report on the excellent clinical data.

Implantica takes a big step forward at its 2nd Annual RefluxStop™ Users Meeting

Retrieved on: 
Martedì, Novembre 14, 2023
EFS, Surgeon, Learning, History, Patient, CET, AFS, Certification, Gastroesophageal reflux disease, Nursing, Dentistry, Pharmaceutical industry, GERD

Implantica conducted its second global users meeting discussing clinical and commercial advancements of RefluxStop™ therapy involving more than 50 attendees including current and also upcoming RefluxStop™ surgeons as well as gastrointestinal physicians from across Europe, UK, US, and Canada.

Key Points: 
  • Implantica conducted its second global users meeting discussing clinical and commercial advancements of RefluxStop™ therapy involving more than 50 attendees including current and also upcoming RefluxStop™ surgeons as well as gastrointestinal physicians from across Europe, UK, US, and Canada.
  • Current, past and upcoming Presidents of the medical societies EFS (European Foregut Society) and AFS (American Foregut Society) were in attendance, including several Board members.
  • "It's rewarding to see the growing numbers of key surgeons around the world offering or interested in offering the RefluxStop™ therapy to patients.
  • The participants in the meeting really experienced the excitement around the impact of the RefluxStop procedure.

This Week in Health News: 12 Stories You Need to See

Retrieved on: 
Venerdì, Novembre 10, 2023
Dentistry, Woman, Coenzyme Q10, Research, Immune system, Congestion, Gold, Design, Database, Omega, Related, Heart failure, Probiotic, Diagnosis, Geography, Subject-matter expert, Gastrointestinal tract, PR Newswire, Sky Go, Fever, News, Dietary supplement, Publishing, GERD

NEW YORK, Nov. 10, 2023 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help journalists covering the healthcare industry stay on top of the week's most newsworthy and popular releases, here's a roundup of stories from the week that shouldn't be missed.

Key Points: 
  • This novel deployment can potentially improve heart disease outcomes for millions of people in communities across the UK.
  • Aplos Medical Achieves a Major Milestone in GERD Treatment with Omega PF™ The Omega PF™ device heralds a paradigm shift in GERD treatment.
  • Designs for Health Launches Innovative Probiotic Toothpaste, PerioBiotic™ Silver
    Similar to the role of probiotics in the gastrointestinal tract, beneficial oral bacteria may help maintain dental and oral health.
  • Purified silver may support overall oral wellness, CoQ10 may help support gum health, and grape seed extract may help healthy inflammatory support.

Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates

Retrieved on: 
Giovedì, Novembre 9, 2023
FDA, Research, Food, PPI, Vonoprazan, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Maintenance, Heartburn, Helicobacter pylori, Tablet, Clinical trial, Hercules, Commercial, New Drug Application, Enzyme inhibitor, NDA, Safety, Leyland Royal Tiger PSU, PARK, Chemistry, Patient, NERD, Gastroesophageal reflux disease, Esophagitis, State, Pharmaceutical industry, Video game, Bank, GERD

Third Quarter 2023 Financial Results:

Key Points: 
  • Third Quarter 2023 Financial Results:
    Net loss for the third quarter ended September 30, 2023, was $43.2 million, compared to $51.1 million for third quarter 2022.
  • Third quarter 2023 net loss included a non-cash charge related to stock-based compensation of $6.1 million compared to $5.8 million for third quarter 2022.
  • Research and development expenses for the third quarter 2023 were $12.3 million, a decrease of $6.7 million compared to $19.0 million for third quarter 2022.
  • General and administrative expenses for the third quarter 2023 were $23.4 million, a decrease of $0.1 million compared to $23.5 million for third quarter 2022.

Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults

Retrieved on: 
Mercoledì, Novembre 1, 2023
GI, FDA, Research, Food, Trial of the century, Vonoprazan, PPI, Conference, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Maintenance, Heartburn, GERD, Tablet, Conference call, PARK, Patient, Gastroesophageal reflux disease, Esophagitis, Pharmaceutical industry

“Erosive GERD can be extremely painful and often has a significant impact on patients.

Key Points: 
  • “Erosive GERD can be extremely painful and often has a significant impact on patients.
  • VOQUEZNA 20 mg also demonstrated non-inferiority to lansoprazole 30 mg in the mean percentage of 24-hour heartburn free days over the healing period.
  • In addition, VOQUEZNA 10 mg was evaluated as a secondary endpoint for relief of heartburn in Erosive GERD patients and demonstrated non-inferiority to lansoprazole 15 mg over six months.
  • ET to discuss the FDA approval and the Company’s U.S. commercialization plans for Erosive GERD and H. pylori infection.

Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults

Retrieved on: 
Lunedì, Ottobre 30, 2023
Neoplasm, PDUFA, Food, Dysgeusia, Rash, Vitamin, Vonoprazan, Abdomen, Clarithromycin, Liver, Chills, Pain, Hypersensitivity, Infection, Allergy, Azithromycin, Rilpivirine, Diarrhea, Liver disease, Tablet, Medicine, Genetically modified bacteria, Drug, Safety, Patient, Chronic pain, DUAL, Catalent, History, Weight loss, Colchicine, GERD, Helicobacter pylori, Fever, Calcium channel, Common, PAS, Jaundice, CGA, Abdominal pain, FDA, Infectious mononucleosis, Headache, Aes, Skin, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Candidiasis, Erythromycin, Urine, Hypertension, Breast milk, Blood, AE, Pharmaceutical industry, Vaccine, Soft drink, Teahouse, Antibiotics, Medicinal plants, Dietary supplement, Birth control, Amoxicillin, Emtricitabine/rilpivirine/tenofovir

The full Prescribing Information for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK can be found here.

Key Points: 
  • The full Prescribing Information for VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK can be found here.
  • VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) are co-packaged prescription medicines for the treatment of a Helicobacter pylori (H. pylori) bacterial infection in adults.
  • It is not known if VOQUEZNA TRIPLE PAK and VOQUEZNA DUAL PAK are safe and effective in children.
  • Stop taking VOQUEZNA TRIPLE PAK or VOQUEZNA DUAL PAK if you are diagnosed with mononucleosis and call your doctor right away.

Aplos Medical Achieves a Major Milestone in GERD Treatment with Omega PF™

Retrieved on: 
Venerdì, Novembre 3, 2023
Nissen fundoplication, EDEN, Gastroesophageal reflux disease, University, Dysphagia, Surgeon, Patient, Medical device, Dentistry, Nissen, GERD

EDEN PRAIRIE, Minn., Nov. 3, 2023 /PRNewswire/ -- Aplos Medical (formerly CT Resources), developer of the next generation Gastroesophageal Reflux Disease (GERD) treatment, proudly announces the successful first implantation of its revolutionary Omega PF™ device.

Key Points: 
  • EDEN PRAIRIE, Minn., Nov. 3, 2023 /PRNewswire/ -- Aplos Medical (formerly CT Resources), developer of the next generation Gastroesophageal Reflux Disease (GERD) treatment, proudly announces the successful first implantation of its revolutionary Omega PF™ device.
  • The Omega PF™ device heralds a paradigm shift in GERD treatment.
  • "We are delighted by this monumental achievement, performed by Dr. Buckley and his team," Aplos Medical President and CEO Dr. Claude Tihon said.
  • "The simple Omega PF™ device is designed to mitigate common issues seen with current GERD treatments.

Evoke Pharma’s Abstract Entitled “Superiority of Nasal Spray Compared to Orally Administered Metoclopramide in Reducing Healthcare Costs in Treating Diabetic Gastroparesis Patients” to Be Presented at The American College of Gastroenterology (ACG) 2023 An

Retrieved on: 
Mercoledì, Ottobre 18, 2023
Patient, Abdominal pain, DGP, Standard of care, American College, Stomach, ACG, University of California, Diabetes, American College of Gastroenterology, Texas Tech University Health Sciences Center El Paso, Gastroparesis, Nausea, GERD, Metoclopramide, Evoke, University, Ondansetron, ER, Cleveland Clinic, DDW, Pharmaceutical industry, MD

These new data build upon the findings presented in plenary session at Digestive Disease Week (DDW) earlier this year which demonstrated significant reductions in healthcare resource utilization (e.g., office, emergency department (ER) and hospital visits, etc.).

Key Points: 
  • These new data build upon the findings presented in plenary session at Digestive Disease Week (DDW) earlier this year which demonstrated significant reductions in healthcare resource utilization (e.g., office, emergency department (ER) and hospital visits, etc.).
  • Upon identifying a major gap in gastroparesis treatment, Evoke developed GIMOTI as a nasal spray to specifically by-pass erratic absorption issues that DGP patients often suffer with medications that are in tablet or pill form.
  • Patients with long-standing diabetes can develop gastroparesis (a delay in stomach emptying).
  • “With the lack of effective oral treatments, and the promising findings for GIMOTI, Evoke is dedicated to make GIMOTI the standard of care for patients with diabetic gastroparesis,” said Dave Gonyer, R.Ph., Evoke Pharma CEO.

Daewoong Pharmaceutical to Participates in CPHI Worldwide 2023, Showcasing Own Novel Drug in the Global Market

Retrieved on: 
Giovedì, Ottobre 19, 2023
Gastroenterology, Exhibition, Rare, Booth, Hall, GERD, Fira (Barcelona Metro), Partnership, Daewoong Pharmaceutical, Autoimmunity, Pain management, Pharmaceutical industry

SEOUL, South Korea, Oct. 19, 2023 /PRNewswire/ -- Daewoong Pharmaceutical is thrilled to announce its participation in CPHI Worldwide 2023, one of the world's premier pharmaceutical industry exhibitions.

Key Points: 
  • SEOUL, South Korea, Oct. 19, 2023 /PRNewswire/ -- Daewoong Pharmaceutical is thrilled to announce its participation in CPHI Worldwide 2023, one of the world's premier pharmaceutical industry exhibitions.
  • The event is scheduled to take place from the 24th to the 26th of October at Fira Barcelona Gran Via, Spain.
  • Especially, Daewoong Pharmaceutical will accelerate to build partnership with global partner for their own novel drug such as GERD treatment (ingredient: Fexuprazan) and Diabetes treatment (ingredient: Enavogliflozin).
  • Additionally, the company has entered into technology export agreements with 18 countries, including China, further solidifying its global reach.